SAN DIEGO, Oct. 18, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that it will be holding its inaugural Investor & Analyst
Day on November 17th in
San Diego, where the Company will
share updates on its clinical development plan for melanoma,
advancement on its intratumoral immunotherapy pipeline of DNA-based
product candidates, and next generation research and device
development. The event will be webcast live via video stream
beginning at 9:00 AM Pacific Time,
and will be available through the Events section under the
Investors tab of OncoSec's website at www.oncosec.com. The
webcast will also be available for replay on the Company
website.
The approximately two-hour agenda for the Investor & Analyst
Day is intended to provide a comprehensive overview of OncoSec.
Presentations will be made by Key Opinion Leaders in the
Immuno-Oncology field, collaborators, and OncoSec's management
team. The presentations will focus on the following areas:
- ImmunoPulse® IL-12 melanoma clinical development
plan and overview of the next registration-directed study
(including a recap of clinical data);
- New research and pre-clinical data from OncoSec's broader
ImmunoPulse® pipeline;
- Pre-clinical and regulatory objectives to initiate a Phase I
clinical study of a new combination molecule candidate; and a,
- Special presentation and announcement regarding the Company's
new device(s) including new research data.
The Company will distribute additional details in subsequent
communications.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse®IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as the
potential to initiate a systemic immune response. OncoSec's lead
program, ImmunoPulse®IL-12, is currently in clinical
development for several indications, including metastatic melanoma
and triple-negative breast cancer. The program's current focus is
on the significant unmet medical need in patients with melanoma who
are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In
addition to ImmunoPulse® IL-12, the Company is also
identifying and developing new immune-targeting agents for use with
the ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
CONTACT:
Sophia Ononye,
PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-host-investor--analyst-day-on-november-17-2016-spotlighting-industry-leading-intratumoral-immunotherapy-pipeline-and-next-generation-research-and-device-development-300346374.html
SOURCE OncoSec Medical Incorporated